Nov 05, 2020 - Teva Pharmaceutical Industries Ltd (NYSE:TEVA) Q3 2020 Earnings Conference Call November 05, 2020, 08:00 ET Company Participants Kevin Mannix - SVP, IR Kare Schultz - President, CEO & Director Eli Kalif - EVP & CFO Brendan O'Grady - EVP, North America Commercial Conference Call Participants Gregory Gilbert - Truist Securities Umer Raffat - Evercore ISI Aaron Gal - Sanford C.
Oct 02, 2020 -
Sep 29, 2020 - AbbVie's (ABBV) elezanumab is presently being evaluated in a phase II study for spinal cord injury.
Sep 19, 2020 - Companies that are built to last are worth considering for your longer-term money, even amid a crisis.
Sep 11, 2020 - Satsuma (STSA) tanks as late-stage study of STS101 (dihydroergotamine [DHE] nasal) powder as an acute treatment for migraine disappoints.
Sep 02, 2020 - One week ago, the DOJ charged Teva for overcharging customers in an alleged price-fixing conspiracy. In this article, I will take a closer look at what this lawsuit means for Teva.
May 04, 2020 - Teva Pharmaceutical Industries (NYSE:TEVA) and collaboration partner Celltrion Healthcare announce the commercial availability of Truxima (rituximab-abbs), a biosimilar to Roche's (OTCQX:RHHBY) Rituxa
Apr 28, 2020 - In the latest trading session, Teva Pharmaceutical Industries Ltd. (TEVA) closed at $10.84, marking a +1.12% move from the previous day.
Apr 28, 2020 - Eagle Pharmaceuticals (NASDAQ:EGRX) and licensee Teva Pharmaceutical Industries (NYSE:TEVA) announce a favorable outcome in a patent dispute from would-be generic competitors to blood cancer med Bende
Apr 27, 2020 - Teva Pharmaceutical Industries (NYSE:TEVA) announces the availability of the autoinjector device for migraine med Ajovy (fremanezumab-vfrm) at a wholesale acquisition cost (WAC) of $603.20.The